PUSHING THE BOUNDARIES OF NEUROLOGY DIAGNOSIS
Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.
“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”
John Mills, Ph.D., co-director, Neuroimmunology Laboratory
OUR DIFFERENCE
News and updates
The latest
After mysterious neurological symptoms began in 2010, Brad Karon, M.D., Ph.D., was diagnosed with paraneoplastic syndrome, a rare condition that led to groundbreaking research and test development at Mayo Clinic. Years later, pulmonary fibrosis and a double lung transplant would test him once again — and redefine his resilience.
Lying in an ICU bed as sick as he could get, Jon Bratsch thought he was past the point of no return. But when a Mayo Clinic Laboratories’ test revealed the source of his dire symptoms, everything changed. Today, Jon’s back to the life and family he loves.
A tenacious fighter, Joy Carol never lost hope that a mysterious condition that had stripped her of her ability to move would be identified. Hope turned into reality when a Mayo Clinic Laboratories test identified the cause of her illness and opened the door to successful treatment.
Mayo Clinic Laboratories’ comprehensive approach to targeted antibody testing played a crucial and lifesaving role in moving Sheila Lewis to recovery from autoimmune encephalitis.
Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.
The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.
While Gregor Heinrich never could have imagined that testicular cancer was related to his problems with his vision and gait, learning he was positive for KLHL11 protein biomarkers meant he could receive treatment for both the cancer and the illness behind it.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of CIDP.
Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision insights on prognosis and treatment options.
Before testing at Mayo Clinic Laboratories, Barbara Domaille, Deborah Neville, Pamela Neville, and Rylie Ronnenberg thought there could be a genetic connection to the hip problems they shared. After the testing, they knew for sure.
John Mills, Ph.D., explains Mayo Clinic Laboratories’ approach to MAG antibody testing. The ELISA-based assay uses higher reference ranges and human MAG antigen to detect MAG antibodies, which are associated with a rare, hard-to-treat condition known as DADS neuropathy.
The discovery of Kelch like protein 11 (KLHL11) IgG as a specific biomarker of neurological autoimmunity associated testicular germ cell tumor.